Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Milrinone in Advanced Heart Failure
NCT02077010Phase 1Completed
- Sponsor
- University of Kansas Medical Center
- Start
- Jun 2020
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of milrinone in heart failure (HF), sponsored by University of Kansas Medical Center. Primary endpoints: Safety Analysis (Patient Reported Adverse Events) at 48 hours and Pharmacokinetic Analysis at 8 hours. Started Jun 2020; status: completed.
02
Drugs
milrinone
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT02077010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02077010.